• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    22nd Century Group Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    11/4/25 6:06:37 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $XXII alert in real time by email
    false 0001347858 0001347858 2025-11-04 2025-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): November 4, 2025

     

     

     

    22nd Century Group, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Nevada   001-36338   98-0468420

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    321 Farmington Road, Mocksville, North Carolina   27028
    (Address of Principal Executive Office)   (Zip Code)

     

    Registrant’s telephone number, including area code: (336) 940-3769

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol   Name of each exchange on which registered
    Common Stock, $0.00001 par value   XXII   NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On November 4, 2025, 22nd Century Group, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Needham & Company, LLC (the “Sales Agent”) under which the Company may issue and sell in a registered offering shares of our common stock having an aggregate offering price of up to $25,000,000 from time to time through or to the Sales Agent (the “ATM Offering”). The Company currently intends to use any net proceeds from this ATM Offering for general corporate purposes, including expansion and acceleration of the Company’s VLN® reduced nicotine content tobacco cigarettes including through partner brands, research and development expenses, procurement and development of additional intellectual property rights and working capital.

     

    Subject to the terms and conditions of the Sales Agreement, each time that the Company wishes to issue and sell shares of common stock, it will notify the Sales Agent and the Sales Agent will use its commercially reasonable efforts, consistent with its sales and trading practices, to solicit offers to purchase the common stock shares under the terms and subject to the conditions set forth in the Sales Agreement.

     

    The Company will pay the Sales Agent 3.00% of the gross proceeds of the sales price per share of common stock sold through the Sales Agent under the Sales Agreement. In addition, the Company will reimburse the Sales Agent for certain fees and disbursements to its legal counsel incurred in connection with entering into the transactions contemplated by the Sales Agreement in an amount not to exceed $100,000 for the establishment of the ATM Offering and $10,000 for each periodic update of the ATM Offering.

     

    Sales of the Company’s common stock through or to the Sales Agent, if any, will be made in transactions that are deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. The Company is not obligated to make any sales of its common stock under the Sales Agreement and may at any time suspend offers under the Sales Agreement. The Sales Agreement will terminate upon the earlier of (i) the sale of all of the Company’s common stock subject to the Sales Agreement, or (ii) termination of the Sales Agreement as permitted therein.

     

    This description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the Sales Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.

     

    The issuance and sale of common stock, if any, by the Company under the Sales Agreement will be offered and sold pursuant to the Company’s Registration Statement on Form S-3 (Registration No. 333-270473) filed with the Securities and Exchange Commission (the “SEC”) on March 10, 2023 and declared effective on March 31, 2023, the base prospectus included therein and the related prospectus supplement, dated November 4, 2025, to be filed with the SEC. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any shares of common stock nor shall there be any sale of shares of common stock in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

     

    A copy of the opinion of Foley & Lardner LLP relating to the legality of the issuance and sale of securities is attached hereto as Exhibit 5.1.

     

    Item 2.02 Disclosure of Results of Operations and Financial Condition

     

    On November 4, 2025, the Company issued an earnings release for the quarter ended September 30, 2025. A copy of the earnings release is furnished as Exhibit 99.1 to this report.

     

    The information in this item shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent, if any, expressly set forth by specific reference in such filing.

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    On November 3, 2025, the Company entered into executive employment agreements with certain executives, including its named executive officers (the “Employment Agreements”). The Employment Agreements have the initial durations indicated in the table below (the “Initial Term”), with automatic one-year renewal periods unless either party provides advance written notice of an intent not to renew.

     

    The Employment Agreements specify the titles and provide for base salaries at the current levels indicated in the table below. They also provide that the executive officers will be eligible to participate in annual cash incentive and long-term cash and equity incentive plans and programs, as well as other employee benefit plans, that are generally provided to the Company’s senior executives from time to time.

     

    The Employment Agreements also provide that, upon an involuntary termination of the executive officer’s employment by the Company without Cause (as defined in the Employment Agreements), or upon a resignation for Good Reason (as defined in the Employment Agreements) upon or within 24 months following a Change of Control (as defined in the Company’s 2021 Omnibus Incentive Plan or any successor incentive plan) (the “Change of Control Employment Period”), the executive officer will receive the severance payment indicated in the table below, as well as subsidized COBRA benefits for the continuation period indicated in the table below.

     

    Executive Officer   Initial Term   Title   Current Base Salary   Severance Payment on Qualifying Termination Not During Change of Control Employment Period   Severance Payment on Qualifying Termination During Change of Control Employment Period   COBRA Continuation Period
     Lawrence  Firestone    42 months    Chief Executive  Officer    $425,000   1.5x sum of base salary plus target bonus   2.5x sum of base salary plus greater of target bonus or prior year’s actual bonus    18 months
     Daniel Otto    39 months    Chief Financial  Officer    $315,000   1.0x sum of base salary plus target bonus   1.5x sum of base salary plus greater of target bonus or prior year’s actual bonus    12 months
     Jonathan  Staffeldt    36 months    General Counsel    $315,000            
     Scott Marion    39 months    Vice President  Manufacturing  Operations    $275,000            
     Robert Manfredonia    36 months    Executive Vice  President Sales  and  Marketing    $275,000            

     

     

     

     

    “Cause” is defined generally in the Employment Agreements to include (a) a willful act or omission that is a material breach of any material obligation under the Employment Agreement or material written policy or procedure and failure to cure, (b) continued willful failure or refusal to substantially perform duties reasonably required, (c) an act of moral turpitude, dishonesty or fraud by, or criminal conviction (excluding non-felony convictions relating solely to vehicle and traffic offenses), (d) material misappropriation of Company property or (e) other willful misconduct that is materially injurious to the financial condition or business reputation of, or is otherwise materially injurious to, the Company. “Good Reason” is defined generally in the Employment Agreements to include (1) a breach by the Company or successor in the Change of Control of the Employment Agreement, (2) a reduction in base salary, percentage of base salary available as incentive compensation or bonus opportunity or benefits, in each case relative to those most favorable to the in effect at any time during the 180-day period prior to the Change of Control or, to the extent more favorable to the executive officer, those in effect at any time after the Change of Control, (3) the removal of the executive officer from, or failure to reelect or reappoint the executive to, any of the positions held with the Company on the date of the Change of Control or any other positions with the Company to which the executive officer has been elected, appointed or assigned, (4) a material adverse change, without the executive officer’s written consent, in the executive officer’s working conditions or status with the Company relative to the most favorable working conditions or status in effect during the 180-day period prior to the Change of Control or, to the extent more favorable to the executive officer, those in effect at any time after the Change of Control, (5) the relocation by more than 50 miles from the principal place of employment on the date 180 days prior to the Change of Control, (6) a requirement to travel 20% in excess of the average number of days per month the executive officer was required to travel during the 180-day period prior to the Change of Control, or (7) a failure to obtain an agreement from a successor in a Change of Control expressly to assume and agree to perform from and after the date of such assignment all of the terms, conditions and provisions imposed by the Employment Agreement.

     

    Upon a qualifying termination, the executive officers will also receive accrued but unpaid benefits. Equity awards will be treated as provided in the applicable equity incentive plan and award agreements. The Employment Agreements also require the executive officers to comply with certain restrictive covenants.

     

    The foregoing description of the Employment Agreements is only a summary and is qualified in its entirety by the form of Executive Employment Agreement that is filed herewith as Exhibit 10.2 and incorporated herein by reference.

     

    Item 9.01(d): Financial Statements and Exhibits.

     

    Exhibit 5.1   Opinion of Foley & Lardner LLP
    Exhibit 10.1   Sales Agreement, dated November 4, 2025, by and between 22nd Century Group, Inc. and Needham & Company, LLC
    Exhibit 10.2   Form of Executive Employment Agreement
    Exhibit 23.1   Consent of of Foley & Lardner LLP (included in Exhibit 5.1)
    Exhibit 99.1   Earnings release dated November 4, 2025
    Exhibit 104   Cover Page Interactive Data File - The cover page XBRL tags are embedded within the inline XBRL document

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      22nd Century Group, Inc.
       
      /s/ Lawrence Firestone
    Date: November 4, 2025 Lawrence Firestone
      Chief Executive Officer

     

     

    Get the next $XXII alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XXII

    DatePrice TargetRatingAnalyst
    7/21/2022$5.00Buy
    Alliance Global Partners
    6/15/2022$5.00Buy
    Craig Hallum
    3/8/2022$6.00Buy
    Roth Capital
    7/23/2021$5.00Outperform
    Cowen
    More analyst ratings

    $XXII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Keys David N was granted 2,118 shares (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    10/6/25 5:01:38 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Keys David N

    3 - 22nd Century Group, Inc. (0001347858) (Issuer)

    8/5/25 4:55:06 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Johnson Anthony L. was granted 2,472 shares, increasing direct ownership by 35,314% to 2,479 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    3/12/25 5:37:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on 22nd Century Group with a new price target

    Alliance Global Partners initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    7/21/22 9:12:19 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on 22nd Century Group with a new price target

    Craig Hallum initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $5.00

    6/15/22 7:42:24 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Roth Capital initiated coverage on 22nd Century Group with a new price target

    Roth Capital initiated coverage of 22nd Century Group with a rating of Buy and set a new price target of $6.00

    3/8/22 9:21:23 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    SEC Filings

    View All

    SEC Form 424B5 filed by 22nd Century Group Inc.

    424B5 - 22nd Century Group, Inc. (0001347858) (Filer)

    11/4/25 5:00:17 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by 22nd Century Group Inc.

    10-Q - 22nd Century Group, Inc. (0001347858) (Filer)

    11/4/25 7:31:01 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - 22nd Century Group, Inc. (0001347858) (Filer)

    11/4/25 6:06:37 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Financials

    Live finance-specific insights

    View All

    22nd Century Group Reports Third Quarter 2025 Financial Results

    Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights. "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of o

    11/4/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports Second Quarter 2025 Financial Results

    VLN® Early Adoption Commercial Activity Expands with Two Partner Brand Launches in Progress – Smoker Friendly and Pinnacle Commenced Pinnacle VLN® Stocking Shipments for Almost 1,000 Locations of Top-5 C-Store Customer, Additional Locations to Come Significantly Expanded State Authorizations for both Reduced Nicotine Content and Conventional Products High Margin Branded Products Business Model Set to Grow Profitably MOCKSVILLE, N.C., Aug. 14, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for th

    8/14/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group Reports First Quarter 2025 Financial Results

    Sales Increase Approximately 50% Sequentially as 2025 Growth Strategy Drives New Sales Activity with Both Internal and External Brand Assets Across Multiple Categories  Preparing First VLN® Partner Brand Shipments with Smoker Friendly and Others Filings Made for New Reduced Nicotine Content and Conventional Product Authorizations in All 50 States Launch of Smoker Friendly Black Label – Tobacco and Water natural style cigarettes MOCKSVILLE, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company that is leading the fight against nicotine dependence and believes smokers should have a choice about their nicotine consumption, today announ

    5/13/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Leadership Updates

    Live Leadership Updates

    View All

    22nd Century Announces First Shipments of Pinnacle VLN® Products to Top 5 C-Store Chain Locations Across 12 States

    Pinnacle VLN® from 22nd Century Gains 2nd Early Adopter to Join Popular Pinnacle Branded Conventional Cigarette Products Already Sold at Top-5 U.S. C-Store Chain MOCKSVILLE, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the first shipments of its new Pinnacle VLN® Gold and Pinnacle VLN® Menthol reduced nicotine content cigarettes into distribution. These initial Pinnacle VLN® shipments will support a sales launch expected on September 1, 2025 at almost 1,000 locations across 12 states for a

    8/4/25 8:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Announces Resignation of John Miller as President of Tobacco

    Helped Establish National Scale Distribution and Launch VLN in More Than 5,000 Stores Across the CountryMocksville, North Carolina--(Newsfile Corp. - May 30, 2024) - 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine harm reduction, today announced that John Miller has resigned as President of Tobacco, effective August 2, 2024. Said Larry Firestone, Chairman and CEO: "I want to thank John for the pivotal role he played in the launch of VLN®, leveraging his decades of industry experience to help us achieve national-scale distribution and establishing a retail presence in more than 5,000 stores across 26 states. He also played a key role in expanding our CMO

    5/30/24 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Group (Nasdaq: XXII) Appoints Accomplished Media Executive Lucille S. Salhany to Its Board

    BUFFALO, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced the appointment of Lucie S. Salhany to its Board of Directors. Ms. Salhany is a highly accomplished media executive with extensive experience in assessing and understanding the consumer landscape, positioning unique products for successful launch utilizing digital media, corporate strategy, and entrepreneurial ventures. She is widely recognized for her appointment as the first woman chair of a major broadcast network, which was e

    9/12/22 4:05:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    11/14/24 5:56:57 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by 22nd Century Group Inc.

    SC 13G - 22nd Century Group, Inc. (0001347858) (Subject)

    10/23/24 7:27:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    22nd Century Group Reports Third Quarter 2025 Financial Results

    Significant Balance Sheet Improvement - Debt Free, Receives $9.5 Million in Non-Dilutive Cash VLN® and Partner VLN® Launches Underway, Rapidly Expanding Store Counts and Availability MOCKSVILLE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced results for the third quarter-ended September 30, 2025, and provided an update on recent business highlights. "The third quarter represents the launch point for a full pivot to a branded products strategy that will drive our future. Multiple brands of o

    11/4/25 6:00:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Announces Receipt of $9.5 Million from Settlement of Insurance Claim

    MOCKSVILLE, N.C., Oct. 28, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced receipt of $9.5 million in cash proceeds pursuant to its previously announced settlement agreement for all claims with its insurer for business interruption related to the Grass Valley incident that occurred in November 2022. "This settlement closes another chapter of our past and solidifies our company's transition from a clean-up to entering a growth phase. We now have a balance sheet with meaningful cash resources that will allow u

    10/28/25 5:07:00 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    22nd Century Launches VLN® with Major C-Store Chain, New Marketing Collateral, Continues to Expand State Authorizations

    VLN® to Commence Sales at Circle K Locations in Illinois, Now Authorized in 45 States and Counting MOCKSVILLE, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today announced the launch of VLN® reduced nicotine content cigarettes at approximately 140 Circle K locations in Illinois. VLN® cigarettes are now authorized for sale in 45 states, with 5 remaining states pending. As part of the launch, the Company also unveiled new marketing and consumer education material featuring the full suite of VLN® combustible

    10/23/25 7:45:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $XXII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Firestone Lawrence bought $10,468 worth of shares (39,000 units at $0.27), increasing direct ownership by 256% to 54,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    9/12/24 5:00:14 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Firestone Lawrence bought $9,829 worth of shares (9,000 units at $1.09), increasing direct ownership by 144% to 15,250 units (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    5/31/24 4:05:20 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Arno Andrew bought $17,490 worth of shares (100,000 units at $0.17) (SEC Form 4)

    4 - 22nd Century Group, Inc. (0001347858) (Issuer)

    1/8/24 8:04:11 PM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care